Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Humira is the company’s blockbuster immunology drug, which has faced competition from biosimilars since 2023. North Chicago, Ill.-based AbbVie had a loss per share of 2 cents, due to an ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...